Cell Growth & Differentiation, Vol 6, Issue 3 263-269, Copyright © 1995 by American Association of Cancer Research

ARTICLES

Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype

CP Minniti, D Luan, C O'Grady, RG Rosenfeld, Y Oh and LJ Helman
Lombardi Cancer Center, Georgetown University Medical School, Washington, DC 20007, USA.

The objective of this study was to examine the role of insulin-like growth factor II (IGF-II) in the pathogenesis of human rhabdomyosarcomas (RMS). We have demonstrated previously that RMS express high levels of IGF-II mRNA, secrete IGF-II peptide, and express both IGF-I and IGF-II receptors. Moreover, we showed that IGF-II functions as an autocrine growth and motility factor in RMS. Since IGF-II is expressed at high levels in fetal muscle cells and RMS are tumors thought to derive from skeletal myoblasts arrested along the normal myogenic pathway, autocrine production of IGF-II by RMS may be an etiological event in the development of this tumor. We have developed a model system which enabled us to study the effects of endogenous IGF-II overprotection in muscle myoblasts. Human cDNA for pre-prohormone IGF-II was transfected into mouse myoblasts in order to achieve high, constant expression of this growth factor, which is normally down-regulated at the end of the differentiation process. Expression of high IGF-II levels resulted in: (a) an increased proliferative rate; (b) impairment of the ability to differentiate into myoblasts; and (c) acquisition of the capability of anchorage-independent growth. No changes in the expression of IGF-I receptors were noted. We conclude that IGF-II overexpression in muscle myoblasts induces morphological and biological changes typical of the malignant phenotype and represents a fundamental event in the pathogenesis of RMS and possibly of other embryonal tumors.

This article has been cited by other articles:

				L. Lu, D. Katsaros, A. Wiley, I. A. Rigault de la Longrais, H. A. Risch, M. Puopolo, and H. Yu The Relationship of Insulin-Like Growth Factor-II, Insulin-Like Growth Factor Binding Protein-3, and Estrogen Receptor-{alpha} Expression to Disease Progression in Epithelial Ovarian Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1208 - 1214. [Abstract] [Full Text] [PDF]

				S. P. Kirk, J. M. Oldham, F. Jeanplong, and J. J. Bass Insulin-like Growth Factor-II Delays Early but Enhances Late Regeneration of Skeletal Muscle J. Histochem. Cytochem., December 1, 2003; 51(12): 1611 - 1620. [Abstract] [Full Text] [PDF]

				W. J. Fredericks, K. Ayyanathan, M. Herlyn, J. R. Friedman, and F. J. Rauscher III An Engineered PAX3-KRAB Transcriptional Repressor Inhibits the Malignant Phenotype of Alveolar Rhabdomyosarcoma Cells Harboring the Endogenous PAX3-FKHR Oncogene Mol. Cell. Biol., July 15, 2000; 20(14): 5019 - 5031. [Abstract] [Full Text]

				L. Zhang, M. Kim, Y. H. Choi, B. Goemans, C. Yeung, Z. Hu, S. Zhan, P. Seth, and L. J. Helman Diminished G1 Checkpoint after gamma -Irradiation and Altered Cell Cycle Regulation by Insulin-like Growth Factor II Overexpression J. Biol. Chem., May 7, 1999; 274(19): 13118 - 13126. [Abstract] [Full Text] [PDF]